NATCO Pharma Limited

NSEI:NATCOPHARM 주식 보고서

시가총액: ₹255.6b

NATCO Pharma 대차 대조표 상태

재무 상태 기준 확인 6/6

NATCO Pharma 의 총 주주 지분은 ₹58.5B 이고 총 부채는 ₹3.7B, 이는 부채 대 자기자본 비율을 6.3% 로 가져옵니다. 총자산과 총부채는 각각 ₹69.1B 및 ₹10.5B 입니다. NATCO Pharma 의 EBIT는 ₹19.7B 이며 이자보상배율은 97.5 입니다. ₹18.5B 의 현금 및 단기 투자금을 보유하고 있습니다.

주요 정보

6.3%

부채 비율

₹3.71b

부채

이자 보상 비율97.5x
현금₹18.49b
주식₹58.53b
총 부채₹10.53b
총 자산₹69.06b

최근 재무 상태 업데이트

Recent updates

We Ran A Stock Scan For Earnings Growth And NATCO Pharma (NSE:NATCOPHARM) Passed With Ease

Oct 13
We Ran A Stock Scan For Earnings Growth And NATCO Pharma (NSE:NATCOPHARM) Passed With Ease

NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market

Aug 13
NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market

If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity

Jul 15
If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity

NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly

Jun 30
NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly

NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors

Jun 14
NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors

NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models

May 30
NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models

Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)

May 09
Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)

Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

Apr 03
Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25

Feb 21
NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25

NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next

Feb 18
NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next

NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement

Feb 17
NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

Jan 25
Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued

Jan 09
An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued

Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

Dec 13
Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued

Sep 30
An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued

Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today

Sep 12
Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today

NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year

Aug 12
NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

Jul 16
Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate

Apr 20
NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate

Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?

Dec 20
Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?

NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's

Aug 12
NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's

Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?

Jun 23
Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?

Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher

Jun 02
Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher

재무 상태 분석

단기부채: NATCOPHARM 의 단기 자산 ( ₹40.2B )이 단기 부채( ₹9.7B ).

장기 부채: NATCOPHARM 의 단기 자산( ₹40.2B )이 장기 부채( ₹804.0M ).


부채 대 자본 내역 및 분석

부채 수준: NATCOPHARM 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: NATCOPHARM 의 부채 대 자기자본 비율은 지난 5년간 11.1% 에서 6.3% 로 감소했습니다.

부채 범위: NATCOPHARM 의 부채는 영업 현금 흐름 ( 326.4% )에 의해 잘 충당되었습니다.

이자 보장: NATCOPHARM 의 부채에 대한 이자 지급EBIT( 97.5 x 적용 범위)로 잘 충당됩니다.


대차 대조표


건강한 기업 발견하기